Skip to main content
. 2021 Mar 1;34(3):228–237. doi: 10.37201/req/019.2021

Table 3.

Activity of different antimicrobials against Pseudomonas aeruginosa collected in Spain in the SMART study (2016-2018)

Antimicrobial No. of isolates tested Range MIC50 MIC90 S
(susceptible, standard dose)
I
(susceptible, increased exposure)
R
(resistant)
Piperacillin-tazobactam 925 ≤2/4 - >64/4 8/4 >64/4 -- 66.8 33.2
Ceftazidime 925 ≤1 - >32 4 >32 -- 71.8 28.2
Cefepime 925 ≤1 - >32 4 32 -- 72.3 27.7
Ceftolozane-tazobactam 925 ≤0.12/4 - >32/4 1/4 4/4 93.0 -- 7.0
Ceftazidime-avibactama 217 ≤0.12/4 - >32/4 2/4 8/4 94.0 -- 6.0
Aztreonam 925 ≤1 - >16 8 >16 -- 79.7 20.3
Imipenem 925 ≤0.12 - >32 1 16 -- 75.5 24.5
Meropenem 925 ≤0.12 - >32 0.5 16 74.7 14.0% 11.3
Tobramycina 217 <= 0.5 - >8 ≤0.5 >8 77.4 -- 22.6
Amikacin 925 ≤4 - >32 ≤4 8 94.6 -- 5.4
Ciprofloxacin 925 ≤0.25 - >2 ≤0.25 >2 -- 63.5 36.5
Levofloxacin 925 ≤0.5 - >4 ≤1 >4 -- 56.0 44.0
Colistin 925 ≤1 - >4 ≤1 ≤1 99.3 -- 0.7
a

Data are only for 2018